2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-114987
    EMD 21657 61711-37-3 98%
    EMD 21657 is a derivative of Piracetam (HY-B0585). EMD 21657 inhibits LOT compound action potential, and enhances the local anesthetic effect of Hexanol (HY-W032022). EMD 21657 exhibits hemolytic effect, and can be used in research about alcoholic encephalopathy syndrome.
    EMD 21657
  • HY-115004
    MM-433593 1006604-91-6 98%
    MM-433593 is a potent and selective inhibitor of fatty acid amide hydrolase-1 (FAAH-1) that is orally administered to inhibit pain, inflammation, and related disorders. Pharmacokinetic studies of MM-433593 in macaques revealed a biphasic elimination profile with a rapid distribution phase and a slower elimination phase, with a systemic clearance of 8-11 mL/min/kg. MM-433593 exhibits moderate oral bioavailability (14-21%) and its metabolism primarily involves oxidation of the methyl group on the indole ring, resulting in a variety of sulfate, glucuronide, or glutathione-conjugated metabolites.
    MM-433593
  • HY-115139
    Fenadiazole 1008-65-7 98%
    Fenadiazole acts as a central nervous system agent to manage insomnia and dreaminess.
    Fenadiazole
  • HY-115272
    GSK894490A 1012035-06-1 98%
    GSK894490A is a non-peptide ghrelin receptor agonist.
    GSK894490A
  • HY-115371
    Butaperazine dimaleate 1063-55-4 98%
    Butaperazine dimaleate is an antipsychotic compound with activity for the detection of vanadium (V). Butaperazine dimaleate can react with vanadium (V) in a phosphoric acid medium to form a red radical cation. The absorption spectrum of butaperazine dimaleate reaches a maximum at 513 nm, which conforms to Beer's law and corresponds to a concentration range of 0.25-5.0 μg/ml. Butaperazine dimaleate has a sensitivity value of 6.1 ng/cm2 and is suitable for the analysis of vanadium steel, minerals, biological samples, and soil samples.
    Butaperazine dimaleate
  • HY-115375
    R 50595 hydrochloride 104860-61-9 98%
    50595 hydrochloride is a selective noncompetitive cisapride antagonist that interferes with the activity of cisapride and BRL 24924. R 50595 hydrochloride has no effect on the response to electrical stimulation at concentrations up to 3 X 10(-7) M. R 50595 hydrochloride antagonizes the effects of cisapride and BRL 24924 in a noncompetitive manner. R 50595 hydrochloride completely abolishes the effects of 5-HT at a concentration of 3 X 10(-7) M and also antagonizes the effects of 5-HT in a noncompetitive manner.
    R 50595 hydrochloride
  • HY-115431
    Antho-rwamide I 114056-25-6 98%
    Antho-rwamide I is a neuropeptide that can be isolated from the sea anemone Anthopleura elegantissima. Antho-rwamide I is resistant to nonspecific aminopeptidases, which increases the stability of the peptide after neuronal release.
    Antho-rwamide I
  • HY-115447
    Clobenpropit 145231-45-4 98%
    Clobenpropit is a potent histamine H3-receptor antagonist. Clobenpropit decreases dopamine release and increases histamine levels in the hypothalamus. Clobenpropit shows antipsychotic-like activities. Clobenpropit causes a resuscitating effect in rats subjected to the hemorrhagic shock.
    Clobenpropit
  • HY-115675
    NC03 568558-66-7 98%
    NC03 is a PI4K2A inhibitor that reduces PI4P levels in the Golgi apparatus and endosomes of cells. NC03 can be used in research on anti-cancer, anti-viral and neurological diseases.
    NC03
  • HY-115706
    13-Dilignoceroyl glycerol 120639-92-1 98%
    13-Dilignoceroyl glycerol is a diacylglycerol containing lignoceric acid (HY-121883 ) at the sn-1 and sn-3 positions. Lignoceric acid is a 24-carbon saturated (24:0) fatty acid, which is synthesized in the developing brain. Lignoceric acid is also a by-product of lignin production. Lignoceric acid can be used for Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy research.
    13-Dilignoceroyl glycerol
  • HY-115724
    FPPQ 1648745-46-3 98%
    FPPQ is a dual-acting 5-HT3 (Ki = 0.9 nM) and 5-HT6 (Ki = 3 nM) receptor antagonist with antipsychotic and procognitive properties.
    FPPQ
  • HY-115739
    RTIL 13 1009376-10-6 98%
    RTIL 13 is a potent inhibitor of dynamin GTPase, with an IC50 of 2.3 μM for dynamin I GTPase. RTIL 13 also targets pleckstrin homology lipid binding domain. RTIL 13 can inhibit receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively.
    RTIL 13
  • HY-115750
    Nω-allyl-L-arginine 139461-37-3 98%
    Nω-allyl-L-arginine is a competitive and reversible inhibitor of bovine brain nitric oxide synthase (nNOS). Nω-allyl-L-arginine can inactivate nNOS in a time-dependent manner. Nω-allyl-L-arginine also is a substrate, producing L-arginine, acrolein, and H2O.
    Nω-allyl-L-arginine
  • HY-115753
    Calpain Inhibitor-1 1448429-06-8 98%
    Calpain Inhibitor-1 (compound 36) is a potent and selective cysteine protease calpain 1 (Cal1) inhibitor (IC50=100 nM; Ki=2.89 μM).
    Calpain Inhibitor-1
  • HY-115760
    Okadaic acid ammonium salt 175522-42-6 98%
    Okadaic acid ammonium salt, a marine toxin, is an inhibitor of protein phosphatases (PP). Okadaic acid ammonium salt has a significantly higher affinity for PP2A (IC50=0.1-0.3 nM), and inhibits PP1 (IC50=15-50 nM), PP3 (IC50=3.7-4 nM), PP4 (IC50=0.1 nM), PP5 (IC50=3.5 nM), but does not inhibit PP2C. Okadaic acid ammonium salt increases of phosphorylation of a number of proteins by inhibiting PP, and acts as a tumor promoter. Okadaic acid ammonium salt induces tau phosphorylation.
    Okadaic acid ammonium salt
  • HY-115763
    3-Aminopropylphosphinic acid 103680-47-3 98%
    3-Aminopropylphosphinic acid (3-APPA) is a phosphonic analog of GABA. 3-Aminopropylphosphinic acid is a potent, selective GABAB receptor agonist.
    3-Aminopropylphosphinic acid
  • HY-115764
    nAChR agonist 2 252870-46-5 98%
    nAChR agonist 2 (compound 8) is a selective alpha4beta2 (α4β2) nAChR agonist (Kd=26 nM).
    nAChR agonist 2
  • HY-115765
    N6-Benzyl-5'-ethylcarboxamido adenosine 152918-32-6 98%
    N6-Benzyl-5'-ethylcarboxamido adenosine is a selective A3 adenosine receptor agonist.
    N6-Benzyl-5'-ethylcarboxamido adenosine
  • HY-115844
    LY-99335 78738-97-3 98%
    LY-99335 is an anesthetic antagonist with behavioral inhibitory activity. LY-99335 exhibits large dose separation at specific doses, indicating its potential in anesthetic antagonism.
    LY-99335
  • HY-115851
    Demethyl PL265 1206514-62-6 98%
    Demethyl PL265 is an enduring dual ENKephalinase inhibitor (DENKi) that holds promise for pain relief.
    Demethyl PL265
Cat. No. Product Name / Synonyms Application Reactivity